Cargando…

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

PURPOSE: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma can be highly effective, but attrition due to progression before TIL administration (32% in prior institutional experience) remains a limitation. We hypothesized that combining ACT with cytotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mullinax, John E., Hall, MacLean, Prabhakaran, Sangeetha, Weber, Jeffrey, Khushalani, Nikhil, Eroglu, Zeynep, Brohl, Andrew S., Markowitz, Joseph, Royster, Erica, Richards, Allison, Stark, Valerie, Zager, Jonathan S., Kelley, Linda, Cox, Cheryl, Sondak, Vernon K., Mulé, James J., Pilon-Thomas, Shari, Sarnaik, Amod A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840208/ https://www.ncbi.nlm.nih.gov/pubmed/29552542 http://dx.doi.org/10.3389/fonc.2018.00044

Ejemplares similares

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
por: Sarnaik, Amod, et al.
Publicado: (2015)

Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma
por: Hall, MacLean, et al.
Publicado: (2015)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model
por: Liu, Hao, et al.
Publicado: (2018)

Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma
por: Garg, Saurabh K., et al.
Publicado: (2023)

Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience
por: Oliver, Daniel E, et al.
Publicado: (2018)

Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
por: Wang, Wenshi, et al.
Publicado: (2012)

Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma
por: Han, Dale, et al.
Publicado: (2015)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
por: Kodumudi, Krithika N., et al.
Publicado: (2016)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Intralesional Rose Bengal in melanoma elicits tumor immunity via HMGB1
por: Liu, Hao, et al.
Publicado: (2015)

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
por: Innamarato, Patrick, et al.
Publicado: (2021)

Immediate triggering of 4-1BB co-stimulation during initiation of tumor-infiltrating lymphocyte (TIL) expansion from melanoma tumors accelerates CD8+ T-cell outgrowth and tumor specificity
por: Chacon, Jessica, et al.
Publicado: (2013)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1
por: Liu, Hao, et al.
Publicado: (2016)

Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014)

Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins
por: Weitman, Evan S, et al.
Publicado: (2019)

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
por: Poch, Michael, et al.
Publicado: (2018)

Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
por: Hall, MacLean S., et al.
Publicado: (2023)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
por: Toomey, Paul, et al.
Publicado: (2013)

Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells
por: Noyes, David, et al.
Publicado: (2022)

Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
por: Mullinax, John E., et al.
Publicado: (2022)

Atypical Fibroxanthoma: Outcomes from a Large Single Institution Series
por: McClure, Erin, et al.
Publicado: (2023)

Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials
por: Sreeraman Kumar, Radhika, et al.
Publicado: (2018)

WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression
por: Mahajan, Nupam P., et al.
Publicado: (2017)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications
por: Aydin, Ahmet Murat, et al.
Publicado: (2021)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature
por: Piña, Yolanda, et al.
Publicado: (2021)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival
por: Smalley, Inna, et al.
Publicado: (2021)

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation
por: Sung, Hyeran, et al.
Publicado: (2016)

The emergence of neoadjuvant therapy in advanced melanoma
por: Sun, James, et al.
Publicado: (2019)

Examination of MARCO Activity on Dendritic Cell Phenotype and Function Using a Gene Knockout Mouse
por: Komine, Hiroshi, et al.
Publicado: (2013)

Ipilimumab
Publicado: (2012)

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
por: Rossfeld, Kara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7paq6i7cslshb0almu1mdvf917